Qube Research & Technologies Ltd Sells 4,342 Shares of Humana Inc. (NYSE:HUM)

Qube Research & Technologies Ltd cut its stake in Humana Inc. (NYSE:HUM) by 77.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,297 shares of the insurance provider’s stock after selling 4,342 shares during the quarter. Qube Research & Technologies Ltd’s holdings in Humana were worth $574,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. FMR LLC grew its stake in shares of Humana by 18.7% in the second quarter. FMR LLC now owns 10,241,494 shares of the insurance provider’s stock worth $4,534,114,000 after acquiring an additional 1,612,251 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Humana by 1.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,089,140 shares of the insurance provider’s stock worth $4,229,872,000 after acquiring an additional 99,832 shares during the period. Vanguard Group Inc. grew its stake in shares of Humana by 0.4% in the second quarter. Vanguard Group Inc. now owns 10,047,296 shares of the insurance provider’s stock worth $4,448,139,000 after acquiring an additional 38,633 shares during the period. Geode Capital Management LLC grew its stake in shares of Humana by 3.7% in the second quarter. Geode Capital Management LLC now owns 2,041,766 shares of the insurance provider’s stock worth $901,182,000 after acquiring an additional 72,772 shares during the period. Finally, Janus Henderson Group PLC grew its stake in shares of Humana by 2.6% in the first quarter. Janus Henderson Group PLC now owns 1,875,237 shares of the insurance provider’s stock worth $786,294,000 after acquiring an additional 46,973 shares during the period. Hedge funds and other institutional investors own 91.85% of the company’s stock.

A number of analysts have recently commented on HUM shares. Seaport Res Ptn reiterated a “neutral” rating on shares of Humana in a research note on Friday, July 9th. JPMorgan Chase & Co. boosted their target price on shares of Humana from $440.00 to $514.00 and gave the company an “overweight” rating in a research report on Friday, July 9th. Zacks Investment Research upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $490.00 target price for the company in a research report on Friday, July 16th. Seaport Global Securities initiated coverage on shares of Humana in a research report on Friday, July 9th. They set a “neutral” rating and a $455.65 target price for the company. Finally, Barclays initiated coverage on shares of Humana in a research report on Thursday, September 9th. They set an “overweight” rating and a $500.00 target price for the company. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $486.92.

Shares of NYSE:HUM opened at $454.48 on Thursday. Humana Inc. has a 1-year low of $370.22 and a 1-year high of $475.44. The firm’s 50 day simple moving average is $408.05 and its two-hundred day simple moving average is $429.14. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.71 and a quick ratio of 1.71. The company has a market capitalization of $58.40 billion, a P/E ratio of 24.02, a P/E/G ratio of 1.42 and a beta of 0.89.

Humana (NYSE:HUM) last released its earnings results on Wednesday, July 28th. The insurance provider reported $6.89 EPS for the quarter, topping the consensus estimate of $6.86 by $0.03. Humana had a net margin of 3.09% and a return on equity of 13.62%. The firm had revenue of $20.65 billion for the quarter, compared to the consensus estimate of $20.51 billion. On average, sell-side analysts anticipate that Humana Inc. will post 21.49 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, October 29th. Stockholders of record on Thursday, September 30th will be issued a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 0.62%. The ex-dividend date is Wednesday, September 29th. Humana’s dividend payout ratio (DPR) is presently 14.93%.

In other news, Director David A. Jr/Ky Jones sold 4,800 shares of the business’s stock in a transaction on Thursday, September 16th. The shares were sold at an average price of $401.00, for a total value of $1,924,800.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.40% of the stock is currently owned by insiders.

Humana Company Profile

Humana Inc engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental benefit plans such as Medicare, and State-based Medicaid contracts.

Read More: What is the Beige Book?

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.